World

Beijing's population drops for six consecutive years

Sep 01, 2024

Beijing [China], September 1: Beijing, China's first megacity to achieve population reduction, has kept its permanent population below the 23 million cap for six consecutive years since 2017, according to a municipal conference held on Thursday.
According to a report by the research team of the Beijing Municipal Committee of the Chinese People's Political Consultative Conference, while Beijing's population remains stable, its distribution is becoming more balanced.
The capital's core functional areas and central urban districts have witnessed constant population declines, while the city's sub-center, new towns, and ecological conservation areas have experienced population growth, according to the report.
According to Xinhua, the report showed that this shift is creating a more distributed population structure, with the proportion of residents in the six central districts decreasing from 60 percent in 2015 to 50 percent by 2023, while the share of the ten outlying districts increased accordingly.
Beijing also stands out for its high concentration of talent, boasting the highest density of talent in China. Three-quarters of this talent pool are concentrated in the six central districts. Additionally, the city's life expectancy in 2020 reached 82.49 years, which is 4.56 years higher than the national average.
The research team emphasised that Beijing should continue its dual approach of relieving overburdened areas while supporting emerging ones. Coordination between central urban districts and new towns as well as integration within the Beijing-Tianjin-Hebei region is crucial.
Gu Shuzhong, a researcher at the Development Research Center of the State Council, suggested that achieving a balanced distribution of work and residential areas across the city is essential, and the city should orderly relocate municipal universities and state-owned enterprises from central districts to outer areas.
Source: Emirates News Agency

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025